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Abstract: Autoimmune manifestations are common in human immu-
nodeficiency virus (HIV) patients. However, the autoantibody spectrum
associated with HIV infection and the impact of antiretroviral therapy
(ART) remains to be determined.
The plasma autoantibody spectrum for HIV patients was charac-
terized by protein microarrays containing 83 autoantigens and con-
firmed by enzyme-linked immunosorbent assay (ELISA). Regulatory, MD, Daniel Byrd met, PhD,
hD, Renzhi Han, PhD, and Qigui Yu, MD, PhD
Higher levels of autoantibody and higher prevalence of elevated
autoantibodies were observed in ART-naive HIV patients compared to
healthy subjects and HIV patients on ART. The highest frequency of
CD33þCD11bþHLA-DRþ cells was observed in ART-naive HIV
patients and was associated with the quantity of elevated autoantibodies.
In addition, CD33þCD11bþHLA-DRþ cells other than Tregs orMDSCs
boost the B cell response in a dose-dependent manner by in vitro assay.
In summary, HIV infection leads to elevation of autoantibodies
while ART suppresses the autoimmune manifestation by decreasing
CD33þCD11bþHLA-DRþ cells in vivo.
The roles of CD33þCD11bþHLA-DRþ cells on disease progression
in HIV patients needs further assessment.
(Medicine 95(15):e3285)
Abbreviations: ART = antiretroviral therapy, HIV = human
s, MDSC = myeloid-derived suppressorcell, Tregs = regulatory T cells.
INTRODUCTION
I ncreased prevalence and titer of circulating autoantibodieshave been reported in patients infected with human immu-
nodeficiency virus (HIV) type 1.1 Up to 68.1% of HIV patients
have circulating antinuclear antibodies (ANAs),1–4 including
autoantibodies against cellular DNA,1,3 small nuclear ribonu-
cleoproteins (snRNPs),1,5 histone H2B,6 Smith (Sm),7 SSA
(Ro),8 and SSB (La).8 In addition to ANAs, autoantibodies
against peripheral blood cells,7 MHC II,7 and phospholipids3,7,9
have also been frequently observed in HIV patients. The
increased incidence and titer of autoantibodies are associated
with lower CD4þ T cell count and higher mortality in HIV
patients who are naive to antiretroviral therapy (ART),3 indi-
cating that autoantibodies may play a pathogenic role or can
serve as a prognostic indicator in HIV infection. In fact,
autoimmune diseases including systemic lupus erythematosus
(SLE), rheumatological syndromes, antiphospholipid syn-
drome, vasculitis, primary biliary cirrhosis, polymyositis,
Graves’ disease, and idiopathic thrombocytopenic purpura have
been frequently reported in HIV/acquired immune deficiency
syndrome (AIDS) patients.1 Therefore, it is important to charac-
terize the spectrum of emerging autoantibodies in HIV patients
as this may shed light on resolving HIV infection related
autoimmune manifestation.
Moreover, in the current era of ART, a plethora of concerns
about autoimmune manifestations in HIV patients have been
raised, which could determine the therapeutic efficiency. There-g the impact of ART on autoantibody
tients is important and valuable for
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Recently, immune regulatory cells, including regulatory T
cells (Tregs, CD25þFoxP3þ) and myeloid-derived suppressor
cells (MDSCs, CD33þCD11bþHLA-DR), are widely
observed to increase in frequency in HIV patients, which is
thought to be responsible for the severe impaired cytotoxic T
cell (CTL) immune response in vivo.10–16 These immune
regulatory cells play pivotal roles in the maintenance of self-
tolerance as well as control of immune activation, particularly
during chronic infections.17–23 In the setting of autoimmune
manifestation caused by HIV infection, it also becomes crucial
to know the roles of Tregs, MDSCs, and other immune cells in
the development of an autoimmune response.
In the present study, we investigated autoantibody profiles
in HIV patients who had maintained undetectable viral loads on
long-term ART, HIV patients who were ART-naı¨ve, and
healthy subjects, and further explored the roles of immune
regulatory cells on regulating the autoimmune response.
METHODS
Study Participants
The study was performed according to a protocol approved
by the Institutional Review Boards for Human Research at the
Indiana University School of Medicine (Indianapolis, IN).
Written informed consent was obtained from each of all partici-
pants before blood collection. Three groups of individuals were
recruited in this study: 20 healthy controls, 17 HIV-infected
ART-naive individuals (CD4 cell counts: 422 cells/mm3,
range 16–1237; viral load: 11,532 copies/mL, range 59–
570,156 copies/mL), and 14 HIV-infected individuals on ART
with undetectable viral load (<50 copies/mL) for at least 2 years
(CD4 cell counts: 556 cells/mm3, range 231–1310). Peripheral
blood from these participants was collected in BD Vacutainer
tubes (containing 143 USP units of sodium heparin per 10-mL
tube, BD, Franklin Lakes, NJ). These blood samples were
separated into peripheral blood mononuclear cells (PBMCs)
and plasma and stored at S80 8C or liquid nitrogen until use.
Autoantigen Protein Microarray
Circulating autoantibody profiles in plasma samples from
uninfected and HIV-infected individuals were determined using
an autoantigen protein microarray as previously described.24,25
The autoantigen protein microarray included 83 autoantigens
and 4 control proteins and was performed in the Microarray
Core Facility of the Texas University (Dallas, TX). Briefly, the
plasma sample diluted at 1:100 was added to the arrays in
duplicate. Net fluorescence intensities (NFIs) were generated by
A Genepix 4000B scanner and Genepix Pro 6.0 software and
normalized using anti-human IgG spotted onto each array.
Values obtained from duplicate spots were averaged. Tests of
significance between groups were carried out using a Student’s
t-test or one-way ANOVA for multiple groups (GraphPad Prism
5.02). Correlations between continuous variables were deter-
mined using Pearson r, and dichotomized variables were com-
pared using Fisher exact test. A P value< 0.05 was considered
significant. Diagrams with row-wise and column-wise cluster-
ing were generated using Cluster and Treeview software (http://
rana.lbl.gov/EisenSoftware.htm).
ELISA
Meng et alAn enzyme-linked immunosorbent assay (ELISA) was
developed to confirm the microarray data and to titrate auto-
antibodies in plasma samples. Briefly, 96-well plates were
2 | www.md-journal.comcoated with individual recombinant human autoantigens includ-
ing centromere protein B (CENP-B), Intrinsic Factor, nuclear
pore glycoprotein-210 (gp210), mitochondrial antibody subtype
M2 (MA-M2), synthetase (PL7), proteins of the nucleolar PM/
Scl macromolecular complex (PM/Scl-75), SP100, signal
recognition particle 54 kDa protein (SRP54), Lupus La protein
or Sjo¨gren syndrome type B antigen (La/SS-B), and small
nucleoprotein particles (snRNPs) such as U1-snRNP-68, U1-
snRNP-A, U1-snRNP-BB0, and U1-snRNP-C (SurModics,
Eden Prairie, MN). After washing and blocking with 5%
FBS/PBS, plates were incubated with serially diluted plasma,
followed by the addition of goat anti-human IgG monoclonal
antibody conjugated with horseradish peroxidase (HRP). Opti-
cal densities (OD) at 450 nm were determined using an ELISA
plate reader (ELX 808 microplate reader, Winooski, VT).
Results were expressed as titers. All ELISA reagents were
purchased from SurModics (Eden Prairie, MN). The observed
endpoint titer for the autoantibody assay was the highest plasma
dilution that yielded an OD greater than the value that defined
the cutoff between positive and negative results.
PBMC Preparation, Cell Depletion, and Sorting
PBMCs were isolated from whole blood by Ficoll centrifu-
gation and analyzed immediately or cryopreserved at 80 8C.
PBMCs were subjected to a positive selection of
CD33þCD11bþ or CD3þCD4þCD25þcells by Fluorescence
Activated Cell Sorting (FACS) using a BD FACS Aria (BD
Biosciences, San Jose, CA). After sorting CD33þCD11bþ or
CD3þCD4þCD25þ cells, the remaining depleted PBMCs were
also harvested for further usage. The isolated CD33þCD11bþ
cells were further sorted into CD11bþHLA-DRþ or
CD11bþHLA-DR by FACS using a BD FACSAria (BD Bios-
ciences, San Jose, CA).
Flow Cytometric Analysis
Cell surface staining with antibodies conjugated with
fluorochromes was performed as previously described.26 The
following anti-human antibodies conjugated with fluoro-
chromes were purchased from eBiosciences (San Diego,
CA): CD14-FITC, CD4-FITC, CD11b-PE, CD25-PE, CD3-
PerCP, CD33-PercpCY5.5, HLA-DR-APC, FoxP3-APC, and
isotype-matched control antibodies conjugated with fluoro-
chrome. Intracellular staining (ICS) with anti-human FoxP3-
PE was performed using the FoxP3 staining buffer set (eBios-
ciences, San Diego, CA) according to the manufacturer’s
instructions. As a heterogeneous cell population, human
MDSCs could be further divided into 2 subsets, monocytic
(M-MDSC, CD14þ) and granulocytic (G-MDSC, CD14/
CD15þ).12,18,20–23 Given that G-MDSCs are unavailable in
Ficoll-prepared PBMCs, we set the gating strategy for M-
MDSCs: CD33þCD11bþ/CD14þHLA-DRLow. Meanwhile,
the gating strategy for Tregs was CD3þCD4þCD25þFoxP3þ.
Cells were collected on a FACSCalibur (BD). The data were
analyzed using FlowJo software (TreeStar, San Carlos, CA).
Appropriate isotype controls were used at the same protein
concentration as the test antibodies, and control staining was
performed during every FACS.
B Cell ELISpot Assay
B cell ELISpot kit from MABTECH (Cincinnati, OH) was
Medicine  Volume 95, Number 15, April 2016used to enumerate the number of autoantibody-secreting B cells
based on the manufacturer’s instructions. Briefly, 96-well plates
with PVDF membrane were coated with 13 mixed autoantigens
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
(4mg/mL of each autoantigen) or anti-human IgG (15mg/mL,
MABTECH) after membrane activation with 70% ethanol.
PBMCs or CD33þ cell-depleted PBMCs from HIV patients
or healthy donors were stimulated with R848 (1 ng/mL)/IL-2
(10 ng/mL), the CD33þ cell-depleted PBMCs were cocultured
with autologous sorted CD33þ cells at various ratios (1:1, 1:5,
1:10) in 24-well plates for 3 days. After harvesting the super-
natant from cultured cells, these cells were washed 3 times and
transferred into 96-well PVDF plates at 2.5 105 cells/well for
overnight culturing. Reactions were visualized using alkaline
phosphatase (AP)-conjugated Streptavidin (MABTECH) and
BCIP/NBT substrate (MABTECH). The number of spots per
106 PBMCs, which represented the number of autoantibody-
producing B cells, was calculated by an ELISpot plate reader
(Bio-Sys GmbH, Karben, Germany).
Statistical Analysis
Data were expressed as mean standard deviation (SD).
Statistical differences were determined by paired Student’s t-
test for paired comparisons, one-way ANOVA with post-tests
for multiple group comparisons and linear regression analysis
for correlations using Prism 5.02 (Graphpad Software, La
Jolla, CA). A P value less than 0.05 was considered to be
significant. The data produced by the current ProtoArray plat-
form were evaluated for the presence or absence of a significant
signal, which is a commonly used approach for data analysis
when using ELISA kits for autoantibody measurement. The
significantly elevated antibodies were determined by P< 0.05
based on one-way ANOVA test among multiple groups.
RESULTS
Autoantibody Profiles Altered in HIV Patients
Eighty-three IgG autoantibody specificities across all
plasma samples were measured via protein microarrays and
analyzed using hierarchical clustering. Most clusters included
antibodies which showed correlation to each other; 10 clusters
could be distinguished from the IgG autoantibody heat map
(Figure 1). Based on the microarray profiling, 15 antibodies
(including CENPB, chromatin, collagen I, H2A, Intrinsic Fac-
tor, gp210, M2, PL7, PM/Scl-75, SP100, SRP54, La/SS-B, SS-
A/SS-B, U1-snRNP-68, and U1-snRNP-A) were significantly
elevated (P< 0.05) in ART-naive HIV patients compared to
healthy controls (Table 1), which cluster together in clusters 2
and 7 (Figure 1). Eight of the 15 autoantibodies (including
collagen I, gp210, H2A, Intrinsic Factor, M2, PL7, PM/Scl-75,
and U1-snRNP-68) were also observed to be significantly
elevated in the HIV patients on ART compared to those from
healthy control subjects (cluster 7, Figure 1 and Table 1). When
compared to HIV patients on ART, ART-naive HIV patients
had 5 significantly elevated autoantibodies (gp210, H2A,
SP100, PM/Scl75, and SRP54) (Table 1).
HIV Patients Had Higher Prevalence of Elevated
Autoantibodies Than Healthy Controls
Mean NFIs of detecting autoantibody in healthy controls
were set as cutoff values for evaluating the changes of auto-
antibodies: >2-fold cutoff as elevated autoantibody. Individu-
ally, HIV patients had a higher prevalence of elevated
autoantibodies than healthy controls as indicated by the Heat-
Medicine  Volume 95, Number 15, April 2016map (Figure 1). The number of elevated autoantibodies per
sample ranged from 0 to 12 (mean¼ 5.4) in the healthy group, 3
to 13 (mean¼ 8.23) in ART-naive HIV patients, and 1 to 14
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(mean¼ 6.64) in HIV patients on ART. Statistical analysis not
only demonstrated that both ART-naive HIV patients and HIV
patients on ART had a higher prevalence of elevated autoanti-
bodies than healthy controls (P< 0.05, Figure 2A), but also
revealed that HIV patients with ART-naive had a higher
prevalence of elevated autoantibodies than those with ART
(P< 0.05, Figure 2A).
Higher Incidence of Individual Autoantibodies in
HIV Patients
In order to understand the prevalence of a specific auto-
antibody in this population, the individual incidence of each
autoantibody was calculated by the ratio of sample numbers
with elevated autoantibody versus the total group size
(Figure 2B). The common 32 autoantibodies did not show
any elevation among all 3 groups. For the remaining 51
autoantibodies, the prevalence ranged from 0% to 20%
(mean¼ 8.24%) in healthy controls, 0% to 58.82%
(mean¼ 15.42%) in ART-naive HIV patients, and 0% to
50% (mean¼ 13.58%) in HIV patients on ART. In summary,
both ART-naive HIV patients on ART showed significantly
higher incidence of specific elevated autoantibody than healthy
controls (P< 0.05, Figure 2B); ART-naive HIV patients pre-
sented with the highest prevalence of specific elevated auto-
antibody and was followed by HIV patients on ART.
Furthermore, for the 15 specifically elevated autoantibodies,
significantly higher titers and elevated frequency was observed
in ART-naive HIV patients when compared to both healthy
controls and HIV patients on ART (P< 0.05, Table 1). The
microarray results established that ART-naive HIV patients had
a higher incidence and higher titers of autoantibodies, and ART
decreased the prevalence and titer of elevated autoantibodies
per sample.
Verification of Plasma Autoantibodies Against 13
Autoantigens Using ELISA
To verify the results obtained by the microarrays, we
selected 13 antigens (CENPB, Intrinsic Factor, gp210, M2,
PL7, PM/Scl-75, SP100, SRP54, La/SS-B, U1-snRNP-68,
U1-snRNP-A, U1-snRNP-BB0, and U1-snRNP-C) and per-
formed ELISA assays. In agreement with the microarray data,
the ELISA data demonstrated that 11 out of the 13 autoanti-
bodies in ART-naive HIV patients and 5 out of the 13 in HIV
patients on ART were significantly higher than the healthy
controls (Figure 2C). Additionally, 3 of 5 autoantibodies
(gp210, H2A, SP100, PM/Scl75, and SRP54) in ART-naive
HIV patients were identified to be higher than those of HIV
patients on ART. Although no significant difference was
observed between these two HIV patients groups, the PM/
Scl-75 autoantibody in ART-naive HIV patients was signifi-
cantly higher than the healthy control, while it was not increased
in HIV patients on ART.
Depletion of CD33RCD11bR Cells Remarkably
Impaired the Autoreactive B Cell Response Ex
Vivo
B cell ELISpot was used to determine whether these
autoantibodies were produced by specific autoreactive B cells
in vivo. For all three groups (healthy control, HIV patients
without treatment, and HIV patients on ART), B cell ELISpot
CD33þCD11bþHLA-DRþ Cells Increase Autoantibodiesassay was performed for 5 PBMCs samples (Figure 3A–C). In
mixed autoantigen coated PVDF membrane wells, visualization
of spots suggested the existence of autoantigen-specific B cells
www.md-journal.com | 3
FIGURE 1. Heat map of the 83 IgG autoantibody reactivities in plasma samples. The average signal intensity of each antigen in each
sample was normalized to the average intensity of total IgG which was printed in 6 replicates on the arrays as an internal control. The NFI
data were used to generate the heat map. For each Ag, the reactivity intensities are depicted on a relative scale, where reactivities above
themean of all samples are colored red, reactivities below are colored green and reactivities close to themean are black.Missing data were
wit
RT,
sity
Meng et al Medicine  Volume 95, Number 15, April 2016as Figure 3A indicated. The strongest autoantigen specific B
cell response was observed in ART-naive HIV patient’ samples,
and healthy control samples had the weakest response
(Figure 3A, B). These results were consistent with the frequency
denoted in gray. The left margin indicates 10 distinct clusters of Ags
healthy controls; HIV-N, HIV patients who were ART-naı¨ve; HIV-A
HIV¼human immunodeficiency virus, NFI¼net fluorescent intenof elevated autoantibodies in these 3 groups; the maximum
prevalence of elevated autoantibodies was in ART-naive HIV
patients, followed by HIV patients on ART (Table 1). Notably,
4 | www.md-journal.comhealthy controls not only had a very low specific B cell response
against autoantigens (Figure 3A, B), but also had relatively low
total IgG production by B cells compared to HIV patients
(Figure 3C), suggesting abnormal B cell activity in
h reactivities that clustered together in the tested samples. Healthy,
HIV patients on ART. Ag¼ antigen, ART¼antiretroviral therapy,
.HIV patients.
MDSCs (originated from CD33þCD11bþ) and Tregs
(CD3þCD4þCD25þFoxP3þ) play critical roles in the regulation
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Elevated Autoantibodies in HIV Patients in Contrast to Healthy People
Name
Group
Healthy
(n¼ 20)
Mean SD
Healthy
Vs
HIV-N
HIV-N
(n¼ 17)
MeanSD
HIV-N
Vs
HIV-A
HIV-A
(n¼ 14)
MeanSD
HIV-A
Vs
Healthy
Healthy
(Elevating
Frequency)
HIV-N
(Elevating
Frequency)
HIV-A
(Elevating
Frequency)
CENP-B 29.48 22.63 P< 0.01 50.13 33.36 37.25 13.81 P> 0.05 0 3/17 1/14
Chromatin 4.16 2.74 P< 0.05 5.81 3.0 5.47 3.69 P> 0.05 2/10 4/17 4/14
Collagen I 0.39 0.65 P< 0.05 0.85 0.63 1.19 1.0 P< 0.05 4/20 10/17 9/14
gp210 13.18 5.89 P< 0.01 23.34 15.26 P< 0.05 18.87 11.27 P< 0.05 0 6/17 2/14
H2A 28.51 15.98 P< 0.01 48.81 21.18 P< 0.05 43.85 16.81 P< 0.01 1/20 7/17 4/17
Intrinsic
Factor
25.36 21.78 P< 0.01 49.96 34.61 52.03 37.33 P< 0.01 1/20 7/17 7/14
La/SS-B 0.49 0.73 P< 0.01 1.51 1.74 0.26 0.34 P> 0.05 0 10/17 1/14
M2 33.76 22.15 P< 0.01 58.86 41.27 54.34 34.18 P< 0.05 1/20 4/17 4/14
PL-7 18.41 15.9 P< 0.01 44.28 30.26 32.32 22.26 P< 0.05 2/20 9/17 3/14
PM/Scl-75 55.21 51.99 P< 0.01 86.51 45.79 P< 0.05 81.92 21.07 P< 0.05 2/20 3/17 3/14
SP100 0.81 1.08 P< 0.01 1.57 1.24 P< 0.05 0.51 0.52 P> 0.05 4/20 8/17 0
SRP54 38.25 28.03 P< 0.01 69.88 41.99 P< 0.05 19.97 8.36 P> 0.05 0 6/17 0
SS-A/SS-B 5.95 2.19 P< 0.05 8.34 3.86 8.08 4.12 P> 0.05 0 2/17 0
U1-snRNP-
68
44.79 25.89 P< 0.05 65.68 31.58 63.37 30.13 P< 0.05 1/20 3/17 3/14
U1-snRNP-A 7.24 9.14 P< 0.05 11.42 4.52 10.98 8.37 P> 0.05 2/10 10/17 3/14
atin
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Medicine  Volume 95, Number 15, April 2016 CD33þCD11bþHLA-DRþ Cells Increase Autoantibodiesof autoimmune responses. To examine which cell types are
involved in the alterations of the autoantibody profile in HIV
patients, we depleted the CD33þCD11bþ or CD3þCD4þCD25þ
cells by FACS and performed B cell ELISpot assays on these
depleted PBMCs. The depletion of CD3þCD4þCD25þ cells had
no obvious effects on the production of autoantibodies or total IgG
in vitro (Figure 3A, B), suggesting that Tregs do not play a
significant role in autoantibody production by B cells in vitro.
However, the depletion of CD33þCD11bþ cells remarkably
impaired the production of both autoantibodies and total IgG in
all 3 groups as shown in Figure 3. In order to further determine
which subpopulation of CD33þCD11bþ cells contributes to this
effect, CD33þCD11bþ cells were subsequently sorted into
CD33þCD11bþHLA-DRþ cells and CD33þCD11bþHLA-DR
cells (mainly M-MDSCs). These cells were cocultured with
CD33þCD11bþ cell-depleted PBMCs at indicated ratios
(Figure 3A, B). Interestingly, we observed that the
CD33þCD11bþHLA-DRþ cells significantly promoted the
production of both autoantibodies and total IgG in a
dose-dependent manner, while the CD33þCD11bþHLA-DR
cells had no effect (Figure 3A–C). These data suggest
that the CD33þCD11bþHLA-DRþ cells rather than the
CD33þCD11bþHLA-DR cells promote antibody production.
Notably, the CD33þCD11bþHLA-DRþ cells showed similar
effects on increasing antibody production in both healthy controls
and HIV patients, which suggests that these cells play a role in
boosting B cell response.
Dramatic Elevation of CD33RCD11bRHLA-DRR
Cells in the Peripheral Blood of ART-Naive HIV
Patients
To evaluate the correlation between the quantity of
HIV-N, ART-naive HIV patients; HIV-A, HIV patients on ART; elev
CENP-B¼ centromere protein B, HIV¼ human immunodeficiency viruCD33þCD11bþHLA-DRþ cells and the alteration of the auto-
antibody spectrum, we compared the frequency of M-MDSCs
(CD33þCD11bþHLA-DR) cells, CD33þCD11bþHLA-DRþ
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.cells, and Tregs (CD3þCD4þCD25þFoxP3þ) in PBMCs from
HIV-seropositive subjects (n¼ 33) with healthy subjects
(n¼ 12). The CD33þCD11bþHLA-DRþ cells, accounting for
nearly 90% of the CD33þCD11bþ cell population, in ART-
naive HIV patients had a significantly higher frequency than
both healthy controls and HIV patients on ART (P< 0.01), as
shown in Figure 3. For the CD33þCD11bþHLA-DR cells,
over 95% are CD14þ cells, namely M-MDSCs (M-MDSCs
gate, Figure 4). When compared to healthy controls, the fre-
quency of both M-MDSCs and Tregs were significantly elev-
ated in ART-naive HIV patients or HIV patients on ART, which
is consistent with previous reports.12,18 However, no significant
difference in the frequency of M-MDSCs and Tregs was noted
between these two HIV patient groups (ART-naive or on ART,
P> 0.05).
Correlational analysis was performed between cell fre-
quency and the occurrence of elevated autoantibodies in the
available samples (from both healthy controls and HIV
patients). Notably, only the frequency of the CD33þCD11bþ
cells, or more specifically the CD33þCD11bþHLA-DRþ cells,
was significantly correlated with the occurrence of elevated
autoantibodies (P< 0.05) (Figure 4). These results support the
conclusion that the CD33þCD11bþHLA-DRþ cells play an
important role in the autoimmune manifestation caused by
HIV infection, while the M-MDSCs and Tregs have no direct
association with the emergence of autoantibodies in HIV
patients. In order to understand the roles of
CD33þCD11bþHLA-DRþ cells in the disease progression,
we further performed correlational analysis between CD4 count
and CD33þCD11bþ HLA-DRþ cells or elevated autoanti-
bodies. In the HIV patients on ART, there was little correlation
between CD4 count and the frequency of autoantibodies or the
frequency of CD33þCD11bþHLA-DRþ cells. In the ART-
g frequency, ratio of samples with >2-folds healthy mean in the group.
D¼ standard deviation.naive HIV patients, a weak correlation (P¼ 0.0486,
R¼ 0.235) between CD4 count and the frequency of
CD33þCD11bþHLA-DRþ cells was identified (Supplement
www.md-journal.com | 5
FIGURE 2. Comparative analysis of quantity and individual incidence of elevated autoantibodies in 3 groups and confirmation of varied
autoantibodies levels detected byMicroarray and by ELISA. (A) The quantity of elevated autoantibodies per sample in healthy groups, HIV
patients without treatment, and HIV patients on ART. (B) Incidence of autoantibodies in healthy group, HIV patients without treatment
and HIV patients with ART, respectively. (C) ELISA confirmation of plasma autoantibody against 13 autoantigens. Serial dilution was used
to determine the final titer of autoantibodies in plasma, and 2-folds of the averaged negatives were considered as the cutoff. Data are
presented as mean averageSD for each of the antigens analyzed. A P-value less than 0.05 was considered statistically significant.
Significant difference between HIV patients and healthy control,

significant difference between HIV patients on ART groups and HIV
patients without treatment as well as healthy control. ART¼antiretroviral therapy, ELISA¼ enzyme-linked immunosorbent assay,
Meng et al Medicine  Volume 95, Number 15, April 2016Figure 1, http://links.lww.com/MD/A871). Additionally, although
no significant correlation between CD4 and autoantibodies was
observed in ART-naive HIV patients, most patients with extre-
HIV¼human immunodeficiency virus, SD¼ standard deviation.mely low CD4 counts (<300 cells/mL) displayed more than 8
elevated autoantibodies (Supplement Table 1, http://links.lww.
com/MD/A871).
DISCUSSION
Autoimmunity has long been recognized to be associated
with HIV infections. However, the complex nature of the
mechanism of the autoimmune response in vivo, and minimal
number of studies characterizing the spectrum of plasma auto-
antibodies in HIV patients in the presence or absence of ART
implied that emerging autoantibodies in primary HIV patients is
nonspecific.1–3 Therefore, it is crucial to evaluate whether there
is a specific autoantibody profile related to HIV infection. In
this study, we identified emerging autoantibody profiles in
respect to HIV infections from 3 observations. First, altered
autoantibody profiles were observed in ART-naive HIV patients
and HIV patients on ART compared to healthy controls. Fifteen
autoantibodies in ART-naive HIV patients and 8 of 15 in HIV
6 | www.md-journal.compatients on ART were significantly higher than that in healthy
controls. Meanwhile, 5 of 15 autoantibodies in ART-naive HIV
patients were significantly higher than that of HIV patients on
ART. Additionally, the highest titer of the 15 specific elevated
autoantibodies was also observed in ART-naive HIV patients.
This study not only characterizes the spectrum of the plasma
autoantibody profile, but also reveals the possibility of ART
improving the autoimmunemanifestation by decreasing the titer
and incidence of autoantibodies in HIV patients.
Second, autoantibodies also displayed a significantly
higher incidence in HIV patients than healthy controls. Particu-
larly, the higher incidence of 15 specific autoantibodies is 2–10/
17 in ART-naive HIV patients and 0–4/20 in healthy controls.
Statistical analysis also confirmed that these 15 specific auto-
antibodies had a significantly higher prevalence in HIV patients
(both ART-naive patients and patients on ART) than healthy
controls. Finally, autoantibody-producing B cells were con-
firmed by B cell ELISpot. Similar to the order of interaction of
autoantibodies from the 3 groups against autoantigens, the
strongest autoreactive B cell response was found in the
ART-naive HIV group, followed by HIV patients on ART,
and healthy controls had the weakest response. Collectively, we
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. B cell ELISpot assay. PBMCs and CD33þ cell-depleted PBMCs were stimulated with R848 (1ng/mL)/IL-2 (10ng/mL) and
cultured alone or coculturedwith autologous isolated CD33þ cells at indicated ratios in 24-well plates for 3 days before performing ELISpot
and cytokine detection. (A) Representative samples of ELISpot assay. Autoantigen specific assay was performed with 13 mixed
autoantigens, while total IgG assays were performed with anti-human IgG. (B) Statistical analysis of autoantigen-specific circulating
B cells in direct andmemory B cell ELISpot. The autoantigen-specific spot-forming cells were presented as a concentration of positive spot-
forming cells per 105 B cells on the y-axis. The x-axis shows different groups. (C) Statistical analysis of total IgG secreting B cells in direct
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Medicine  Volume 95, Number 15, April 2016 CD33þCD11bþHLA-DRþ Cells Increase Autoantibodieshave established the autoantibody spectrum related to HIV
infection for the first time, and our data suggest that ART
improves the autoimmune response during HIV infection.
Although some aspects of HIV immunopathogenesis
relevant to the promotion of autoimmunity were discussed
previously, the mechanisms underlying the interplay between
immune dysregulation and the impact of ART may provide
important insight into understanding the manifestations of
autoimmunity during HIV infection.26–32 Immune dysregula-
tion is a hallmark of HIV infection, which may be caused by
altering the frequency of function of immune cells such as T
cells, B cells, and other immune cells.27–35 Recent studies
indicated that elevated immune regulatory cells (MDSCs and
Tregs) are associated with progression of HIV/AIDS.12–15
Despite the lack of common biomarkers, MDSCs are believed
and memory B cell ELISpot. The total IgG spot-forming cells were
PBMCs on the y-axis. The x-axis shows different groups. Data are
ELISpot¼B cell enzyme-linked immunospot, PBMC¼peripheral bto be derived from CD33þCD11bþ cells. Our in vitro studies
demonstrated that depletion of CD33þCD11bþ cells, but not
CD3þCD4þCD25þ cells leads to a remarkably impaired B cell
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.response. As MDSCs encompass a heterogeneous population,
CD33þCD11bþ cells strongly promote the B cell response
in vitro. In these cells, more than 90% of the cells are
CD14 positive and/or HLA-DR positive and <10% are
MDSCs. Unexpectedly, additional experiments with sorted
CD33þCD11bþ cells indicated that CD33þCD11bþHLA-
DR cells (mainly MDSCs) have no effect on secretion of
autoantibodies or total IgG in vitro. On the contrary,
CD33þCD11bþHLA-DRþ cells promoted a robust production
of both autoantibodies and total IgG in a dose-dependent
manner. Notably, CD33þCD11bþHLA-DRþ cells displayed
the same role in HIV patients and healthy controls, which
suggest that CD33þCD11bþHLA-DRþ cells contribute to the
development of autoimmunity in a nonspecific way.
Based on the previously mentioned results, we proposed
esented as a concentration of positive spot-forming cells per 10
sented as mean average SD for each of the antigens analyzed.
d mononuclear cell, SD¼ standard deviation.that an increase in the CD33þCD11bþHLA-DRþ cells would
promote the production of autoantibodies in vivo. Flow cyto-
metry data from all participants displayed a significant increase
www.md-journal.com | 7
dysfunction caused by HIV infection and reconstitution of
FIGURE 4. Frequency of CD33þCD11bþ cells, monocytic MDSCs, granulocytic MDSCs, CD33þCD11bþHLA-DRþ cells, and Tregs in
peripheral blood of healthy controls and HIV infected individuals. (A, B) Gating strategy of M-MDSCs and G-MDSCs by flow cytometric
analysis. CD11bþCD33þ/high cells were first selected from live PBMCs (A), and the CD14þ/HLA-DR/low population as M-MDSC (B). (C,
D, F) Comparison of M-MDSCs, CD33þCD11bþHLA-DRþ cells, and Tregs between HIV-infected ART-naive individuals, healthy controls,
ant þ þ
by
us,
Meng et al Medicine  Volume 95, Number 15, April 2016in the frequency of CD33þCD11bþHLA-DRþ cells in ART-
naive HIV patients rather than HIV patients on ART or healthy
controls. Meanwhile, the frequency of CD33þCD11bþHLA-
DRþ cells positively correlated with the occurrence of elevated
autoantibodies per sample in both healthy controls and HIV
patients. The above results suggest that a higher
CD33þCD11bþHLA-DRþ cell frequency promotes increased
production of elevated autoantibodies in ART-naive HIV
patients, and ART can improve autoimmunity in HIV patients,
which is at least partly due to decreased frequency of
CD33þCD11bþHLA-DRþ cells.
Although MDSCs and Tregs have been documented to a
play critical role in immune tolerance and the control of the
autoimmune response, the effects of MDSCs and Tregs may be
dependent on the interaction between these immune regulatory
cells and T cells.10–12,32–35 Notably, T cell exhaustion and
impaired function caused by HIV infection may hinder the
function of these immune regulatory cells against the develop-
ment of autoimmunity. On the contrary, immune activation
and immune dysfunction lead to increased CD33þCD11bþ
HLA-DRþ cells, which promote the development of autoim-
and HIV-infected individuals on ART. P<0.05: statistically signific
cells frequencies and signal intensity of 12 autoantibody titers
ART¼antiretroviral therapy, HIV¼human immunodeficiency vir
intensity.munity in a nonspecific way. The proposed mechanism of
CD33þCD11bþHLA-DRþ cells in the promotion of the auto-
immune response may shed light on these controversies in HIV
8 | www.md-journal.cominfection and pathogenesis; an increased population of
CD33þCD11bþ cells promotes persistent immune activation
and autoimmune response, while an increased population of
suppressor cells may lead to impaired T cell immunity.
In this study, we reveal that HIV infection leads to
autoimmune manifestation with a specific spectrum of circulat-
ing autoantibodies, meanwhile ART may improve the auto-
immune condition and alter their autoantibody spectrum by
reducing the number of CD33þCD11bþHLA-DRþ cells. How-
ever, a better understanding of the mechanism behind the effect
of ART on the CD33þCD11bþHLA-DRþ cells may provide the
necessary insight for resolving the mechanism of immune
difference from controls. (E) Correlation between CD33 CD11b
microarray (NFI) (r2¼0.2703, P¼0.0404; linear regression).
MDSC¼myeloid-derived suppressor cell, NFI¼net fluorescentthe immune system in HIV patients, which requires
further investigation.
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